Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology

17/Oct/2018

Dr. Mahant to assist with the development of screening criteria to identify patients who are most likely to receive clinical benefit from the ValloVax immunotherapy.

Read Full Article About Businesswire.com

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

24/Sep/2018

Today, Batu Biologics announced the release of the Starve The Tumor Video Blog, a series of informational videos and articles designed to provide background information on our lead therapeutic ValloVax.

Read Full Article About Businesswire.com

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

20/Aug/2018

Batu Biologics, a clinical stage immuno-oncology Company, announced today the filing of a patent application covering methods of selecting patients likely to respond to ValloVax.

Read Full Article About Businesswire.com

Batu Biologics Files Patent on Patient Selection for Right to Try Law

26/Jul/2018

Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try Law.

Read Full Article About Businesswire.com

Batu Biologics Recruits Nobel Prize Winner Bruce Beutler

11/Jun/2018

Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board.

Read Full Article About Businesswire.com

Batu Biologics Releases Shareholder Letter

31/May/2018

Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareholders of the Company, providing a comprehensive update on the clinical progress of the ValloVax immune therapy.

Read Full Article About Businesswire.com

Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

24/Mar/2018

Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco Marincola as the Chairman of the Company’s Clinical Advisory Board.

Read Full Article About Businesswire.com

Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium

15/Mar/2018

Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally renowned panel of biotechnology companies focusing on immunotherapy.

Read Full Article About Businesswire.com

Batu Biologics CEO Selected for Lyfebulb Oncology Award

1/Mar/2018

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology.

Read Full Article About Businesswire.com

Batu Biologics Raises $1.3 Million in Equity Crowdfunding

25/Dec/2017

Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.

Read Full Article About Businesswire.com
1 2 3 6
?>